Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
News|Videos|December 23, 2024
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
Author(s)Amer Zeidan, MD
Dr. Amer Zeidan presents interim Phase 1a results from the KOMET-007 trial, demonstrating the safety and robust clinical activity of ziftomenib combined with intensive chemotherapy (7+3) in newly diagnosed adverse-risk NPM1-mutated and KMT2A-rearranged acute myeloid leukemia, highlighting high response rates and promising survival outcomes.
Advertisement
Advertisement
Related to this article
Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss optimizing first-line treatment selection and second-line sequencing in EGFR-mutated NSCLC.
MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.
T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Three new articles from The Lancet Hematology published today examine how clinicians and researchers can better identify, track and measure the effects of blood cancer treatments on patients during treatment and over the long term.
During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.
R. Lor Randall, MD, FACS, discusses novel precision surgery techniques that are making progress in sarcoma care.
Advertisement
Advertisement
Trending on OncLive
1
European Commission Approves T-DXd Plus Pertuzumab for First-Line HER2+ Metastatic Breast Cancer
2
Dr Huffman on the Mechanism of Action of INCB161734 in KRAS G12D–Mutated Metastatic Pancreatic Cancer
3
TP53 Status and Treatment Toxicity Burden Guide Sequencing in EGFR-Mutated NSCLC
4
FDA Grants Fast Track Designation to MT027 for Recurrent Glioblastoma
5